Ad is loading...
ARDX
Price
$5.50
Change
-$0.04 (-0.72%)
Updated
Dec 3 closing price
91 days until earnings call
PTGX
Price
$41.25
Change
-$2.01 (-4.65%)
Updated
Dec 3 closing price
104 days until earnings call
Ad is loading...

ARDX vs PTGX

Header iconARDX vs PTGX Comparison
Open Charts ARDX vs PTGXBanner chart's image
Ardelyx
Price$5.50
Change-$0.04 (-0.72%)
Volume$2.68M
CapitalizationN/A
Protagonist Therapeutics
Price$41.25
Change-$2.01 (-4.65%)
Volume$680.91K
CapitalizationN/A
ARDX vs PTGX Comparison Chart
Loading...
ARDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ARDX vs. PTGX commentary
Dec 04, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARDX is a Buy and PTGX is a Buy.

COMPARISON
Comparison
Dec 04, 2024
Stock price -- (ARDX: $5.50 vs. PTGX: $41.25)
Brand notoriety: ARDX and PTGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARDX: 62% vs. PTGX: 105%
Market capitalization -- ARDX: $1.31B vs. PTGX: $2.58B
ARDX [@Biotechnology] is valued at $1.31B. PTGX’s [@Biotechnology] market capitalization is $2.58B. The market cap for tickers in the [@Biotechnology] industry ranges from $485.15B to $0. The average market capitalization across the [@Biotechnology] industry is $2.71B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARDX’s FA Score shows that 0 FA rating(s) are green whilePTGX’s FA Score has 2 green FA rating(s).

  • ARDX’s FA Score: 0 green, 5 red.
  • PTGX’s FA Score: 2 green, 3 red.
According to our system of comparison, PTGX is a better buy in the long-term than ARDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARDX’s TA Score shows that 4 TA indicator(s) are bullish while PTGX’s TA Score has 5 bullish TA indicator(s).

  • ARDX’s TA Score: 4 bullish, 5 bearish.
  • PTGX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, PTGX is a better buy in the short-term than ARDX.

Price Growth

ARDX (@Biotechnology) experienced а +2.80% price change this week, while PTGX (@Biotechnology) price change was -7.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.35%. For the same industry, the average monthly price growth was -1.83%, and the average quarterly price growth was +8.53%.

Reported Earning Dates

ARDX is expected to report earnings on Mar 05, 2025.

PTGX is expected to report earnings on Mar 18, 2025.

Industries' Descriptions

@Biotechnology (+1.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($2.58B) has a higher market cap than ARDX($1.31B). PTGX YTD gains are higher at: 79.895 vs. ARDX (-11.290). PTGX has higher annual earnings (EBITDA): 152M vs. ARDX (-53.06M). PTGX has more cash in the bank: 469M vs. ARDX (190M). PTGX has less debt than ARDX: PTGX (10.9M) vs ARDX (104M). PTGX has higher revenues than ARDX: PTGX (324M) vs ARDX (252M).
ARDXPTGXARDX / PTGX
Capitalization1.31B2.58B51%
EBITDA-53.06M152M-35%
Gain YTD-11.29079.895-14%
P/E RatioN/A15.05-
Revenue252M324M78%
Total Cash190M469M41%
Total Debt104M10.9M954%
FUNDAMENTALS RATINGS
ARDX vs PTGX: Fundamental Ratings
ARDX
PTGX
OUTLOOK RATING
1..100
661
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
10045
SMR RATING
1..100
9721
PRICE GROWTH RATING
1..100
6142
P/E GROWTH RATING
1..100
5724
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PTGX's Valuation (65) in the Biotechnology industry is somewhat better than the same rating for ARDX (98). This means that PTGX’s stock grew somewhat faster than ARDX’s over the last 12 months.

PTGX's Profit vs Risk Rating (45) in the Biotechnology industry is somewhat better than the same rating for ARDX (100). This means that PTGX’s stock grew somewhat faster than ARDX’s over the last 12 months.

PTGX's SMR Rating (21) in the Biotechnology industry is significantly better than the same rating for ARDX (97). This means that PTGX’s stock grew significantly faster than ARDX’s over the last 12 months.

PTGX's Price Growth Rating (42) in the Biotechnology industry is in the same range as ARDX (61). This means that PTGX’s stock grew similarly to ARDX’s over the last 12 months.

PTGX's P/E Growth Rating (24) in the Biotechnology industry is somewhat better than the same rating for ARDX (57). This means that PTGX’s stock grew somewhat faster than ARDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARDXPTGX
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
77%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 8 days ago
86%
Bullish Trend 13 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
75%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
81%
View a ticker or compare two or three
Ad is loading...
ARDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRLOX18.420.05
+0.27%
BlackRock Global Allocation R
FBDIX141.83N/A
N/A
Franklin Biotechnology Discovery A
SMLKX22.82N/A
N/A
Shelton S&P Smallcap Index K
LSSNX33.07-0.08
-0.24%
Loomis Sayles Small Cap Growth N
GURPX34.54-0.24
-0.69%
NAA Risk Managed Real Estate P

ARDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARDX
1D Price
Change %
ARDX100%
-0.72%
VCYT - ARDX
45%
Loosely correlated
-1.04%
HRTX - ARDX
41%
Loosely correlated
-3.28%
PTGX - ARDX
40%
Loosely correlated
-4.65%
NKTX - ARDX
39%
Loosely correlated
-10.89%
BCRX - ARDX
39%
Loosely correlated
-2.57%
More

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with ACLX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
-4.65%
ACLX - PTGX
41%
Loosely correlated
-7.39%
RCKT - PTGX
41%
Loosely correlated
-6.32%
ARDX - PTGX
40%
Loosely correlated
-0.72%
VIR - PTGX
40%
Loosely correlated
+12.88%
VRDN - PTGX
40%
Loosely correlated
-4.33%
More